With rage surging over claims of price gouging, EpiPen manufacturer Mylan took a page from Turing’s playbook today. CEO Heather Bresch told CNBC that the company is taking “immediate action” to make the life-saving auto-injectors available to any patients that need one. The company will expand discounts and eligibility of its customer assistance program.

However, Mylan gave no sign that it will lower the EpiPen’s list price, which the company has hiked up more than 400 percent in recent years. Though an EpiPen only costs a few dollars to make and can reverse deadly allergic reactions, they now can cost more than $600.

Bresch, seen as the mastermind of the price hike and currently one of the highest paid executives in the industry, tried instead to shift the conversation to problems in the American healthcare system.

In what can only be described as a perplexing interview with CNBC, Bresch said:

No one's more frustrated than me… My frustration is, the list price is $608. There is a system. I laid out that there are four or five hands that the product touches, and companies that it goes through before it ever gets to that patient at the counter. Everyone should be frustrated. I'm hoping that this is an inflection point for this country.

She added:

All involved must also take steps to help meaningfully address the US health care crisis… and we are committed to do our part to drive change in collaboration with policymakers, payers, patients, and health care professionals.

It may appear bold to dodge calls to lower the list price—particularly as the company faces claims that it is a "vulture" guilty of limitless greed—and instead deflect blame to broader problems. However, Bresch’s response echoes that of Turing Pharmaceutical’s in the wake of its own price gouging allegations. Turing faced intense backlash after it raised the price of a life-saving drug, Daraprim, by more than 5,000 percent last fall. Though Turing initially hinted that it would indeed scale back the drug's list price, it instead unveiled discount plans and deals for hospitals.

"We pledge that no patient needing Daraprim will ever be denied access," Nancy Retzlaff, Turing's chief commercial officer, said in a news release at the time. Like Bresch, she hinted at broader, system-wide problems, adding, "Drug pricing is one of the most complex parts of the healthcare industry. A drug's list price is not the primary factor in determining patient affordability and access.”

Despite Turing's discounts and deals, documents released in a Congressional hearing a few months later revealed that some patients faced $16,000 co-pays while Turing executives were handed six-figure bonuses.